Djomnang, Liz-Audrey Kounatse
Li, Carol
Mzava, Omary
Cheng, Alexandre Pellan
Chang, Adrienne
Lenz, Joan Sesing
Suthanthiran, Manikkam
Lee, John R.
Dadhania, Darshana M.
De Vlaminck, Iwijn
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (R01AI151059)
National Center for Advancing Translational Sciences (UL1TR002384)
National Institutes of Health (R01AI146165)
Article History
Received: 8 November 2023
Accepted: 10 February 2024
First Online: 13 May 2024
Competing interests
: OM, APC, and AC are listed as inventors on submitted patents pertaining to cell-free nucleic acids (US patent applications 63/237,367 and 63/429,733). I.D.V. is a member of the Scientific Advisory Board of Karius Inc., Kanvas Biosciences and GenDX. I.D.V. is listed as an inventor on submitted patents pertaining to cell-free nucleic acids (US patent applications 63/237,367, 63/056,249, 63/015,095, 16/500,929, 41614P-10551-01-US) and receives consulting fees from Eurofins Viracor. DMD is a consultant for CareDx and is engaged in clinical investigation sponsored by CSL Behring and AlloVir. Other authors declare no conflict of interest.